GlassScriptPhysician profile
Alex D Michelson
NPI 1255372389
$4,565.69
in general payments reported to CMS, 2019-2025
21 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $378 · 2021: $444 · 2022: $529 · 2023: $877 · 2024: $910 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,615 · Consulting Fee: $200 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,614.72 |
| Consulting Fee | $200.00 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $873.52 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $705.00 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $686.37 | 2019-2025 | Spravato |
| Bausch Health US, LLC | $550.69 | 2019-2025 | Aplenzin |
| Ironshore Pharmaceuticals INC. | $296.40 | 2019-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $201.00 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
| Adlon Therapeutics L.P. | $194.97 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $169.22 | 2020-2025 | Rexulti |
| Corium, LLC | $130.03 | 2021-2023 | Azstarys |
| Tris Pharma INC | $112.81 | 2023-2024 | Dyanavel Xr |
| Almatica Pharma LLC | $96.36 | 2024 | Loreev Xr |
| Allergan, INC. | $81.58 | 2019-2020 | |
| Noven Therapeutics, LLC | $81.23 | 2023 | Secuado, Xelstrym |
| Eisai INC. | $50.11 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $37.52 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $25.57 | 2024 | Ingrezza |
| Tempus Ai, INC | $22.46 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.02 | 2022 | |
| Avanir Pharmaceuticals, INC. | $15.34 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.49 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Michelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.